Free Trial

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.2% - Here's What Happened

Recursion Pharmaceuticals logo with Medical background

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded down 6.2% on Monday . The stock traded as low as $4.98 and last traded at $4.95. 4,679,937 shares changed hands during mid-day trading, a decline of 71% from the average session volume of 15,996,274 shares. The stock had previously closed at $5.27.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target on the stock. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $7.00.

Read Our Latest Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Up 4.3%

The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $4.82 and a 200-day simple moving average of $6.09. The firm has a market capitalization of $2.27 billion, a PE ratio of -3.16 and a beta of 0.91.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same period in the prior year, the business earned ($0.39) earnings per share. The business's quarterly revenue was up 7.2% compared to the same quarter last year. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC increased its holdings in Recursion Pharmaceuticals by 7.6% during the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after purchasing an additional 2,469,104 shares during the period. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares during the period. Softbank Group CORP. purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $99,152,000. Kinnevik AB publ grew its holdings in shares of Recursion Pharmaceuticals by 12.8% during the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after acquiring an additional 1,528,503 shares during the period. Finally, Novo Holdings A S purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $68,375,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Recommended Stories

Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?

Before you consider Recursion Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.

While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines